UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from __________________ to __________________ Commission File Number 001-11255 State or Other Jurisdiction of Incorporation or Organization Registrant, State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from __________________ to __________________ Commission File Number 001-11255 State or Other Jurisdiction of Incorporation or Organization Registrant, State ...

Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2026 Third Quarter DUBLIN, IRELAND - (February 4, 2026) - STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the thir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 27, 2025 OR Commission File Number 001-36267 Delaware 46-3891989 BLUE BIRD CORPORATION (Exact name of registrant as specified in its charter) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ................................ to . ...

EXHIBIT 99.1 ePlus Reports Third Quarter and First Nine Months Financial Results of Fiscal Year 2026 Double Digit Growth Year Over Year Across Key Metrics Including Net Sales, Gross Profit and Earnings Per Share ~ Raises Fiscal 2026 Guidance and Announces Common Stock Quarterly Dividend of $0.25 Per Share ~ Third Quarter of Fiscal Year 2026 First Nine Months of Fiscal Year 2026 HERNDON, VA – February 4, 2026 – ePlus inc. (NASDAQ: PLUS), a leading provider of technology solutions, today announced financial r ...

Financial Performance - Consolidated net sales for the quarter ended December 31, 2025 were $295.9 million, remaining flat compared to the same prior year period, with a 1% decrease for the six months ended December 31, 2025 at $582.4 million [115]. - Organic revenue for the quarter ended December 31, 2025 remained flat, with a favorable foreign currency exchange impact of 2% and an unfavorable impact of 2% from non-recurring prior year revenue from a business held-for-sale [115]. - Consolidated gross margins for the quarter and six months ended December 31, 2025 were 64.6% and 65.1%, respectively, compared to 65.3% and 64.3% for the same prior year periods [116]. - Non-GAAP adjusted net earnings for the quarter ended December 31, 2025 were $72.1 million, with diluted earnings per share of $0.46, compared to $68.1 million and $0.42 in the prior year [127]. Expenses and Cost Management - Selling, general and administrative expenses decreased by 6% to $113.7 million for the quarter and by 4% to $229.9 million for the six months ended December 31, 2025, primarily due to ongoing cost management initiatives [119]. - Research and development expenses decreased by 8% to $23.1 million for the quarter and by 3% to $47.4 million for the six months ended December 31, 2025, while continuing to make strategic growth investments [120]. Segment Performance - Protein Sciences segment net sales for the quarter ended December 31, 2025 were $215.1 million, a 2% increase, while remaining flat for the six months at $417.3 million [121]. - Diagnostics and Spatial Biology segment net sales for the quarter ended December 31, 2025 were $81.2 million, a 4% decrease, with an operating margin of 10.4% compared to 3.9% in the prior year [123]. Taxation - The effective income tax rate for the quarter and six months ended December 31, 2025 was 25.2% and 22.9%, respectively, compared to 18.6% and 17.5% for the same prior year periods [125]. - The forecasted tax rate for the remainder of fiscal 2026 is expected to range from 25% to 29% [126]. - The non-GAAP adjusted tax rate for the quarter ended December 31, 2025, was 22.3%, compared to 21.5% in the same quarter of 2024 [129]. Cash Flow and Capital Management - As of December 31, 2025, cash and cash equivalents were $172.9 million, an increase from $162.2 million as of June 30, 2025 [130]. - The company generated $110.0 million from operating activities in the six months ended December 31, 2025, down from $148.2 million in the same period of 2024, primarily due to changes in cash payment timing [133]. - Capital expenditures for fixed assets for the six months ended December 31, 2025, were $11.3 million, compared to $16.0 million in 2024, with an expected $18 million for the remainder of fiscal 2026 [135]. - The company paid cash dividends of $24.9 million during the six months ended December 31, 2025, slightly down from $25.4 million in 2024 [138]. - The company made repayments of $86.0 million on its long-term debt during the six months ended December 31, 2025, compared to $19.0 million in the same period of 2024 [140]. - The company has a line-of-credit of $740 million available as of December 31, 2025, governed by a Credit Agreement maturing on August 31, 2027 [130]. - The company expects to meet its cash and working capital requirements for at least the next 12 months through available cash and generated cash from operations [132]. Acquisitions - The company acquired 19.9% of Wilson Wolf for $232 million in fiscal 2023, with a future obligation to acquire the remaining 80.1% by December 31, 2027, contingent on financial milestones [131]. Asset Management - The company received $4.6 million for assets held-for-sale during the six months ended December 31, 2025, compared to $1.8 million in 2024 [137].

For the transition period from __________________________________to __________________________________ Commission file number 001-36504 Weatherford International plc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q ______________________________________ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2025 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 0-5151 ______________________________________ FLEXSTEEL INDUSTRIES, INC. (Exact Name o ...

EXHIBIT 99.1 Star Group, L.P. Reports Fiscal 2026 First Quarter Results For the fiscal 2026 first quarter, Star reported a 10.5 percent increase in total revenue to $539.3 million compared with $488.1 million in the prior-year period, reflecting higher product volumes and an increase in service and installation revenue. The volume of home heating oil and propane sold during the fiscal 2026 first quarter rose by 11.5 million gallons, or 13.9 percent, to 93.9 million gallons, as the additional volume provided ...

SILGAN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS; EXPECTS CONTINUED GROWTH IN 2026 Silgan Holdings Inc. Exhibit 99.1 Adjusted net income per diluted share for the full year of 2025 was $3.72, after adjustments increasing net income per diluted share by $1.02, a 3% increase over adjusted net income per diluted share for the full year of 2024 of $3.62 after adjustments increasing net income per diluted share by $1.04. Adjusted net income per diluted share for the fourth quarter of 2025 was $0.67, af ...